Review Proposal - September 2010
Review of NICE Technology Appraisal Guidance No 133; Omalizumab for severe persistent allergic asthma
Proposal to combine this review with a review of an on-going technology appraisal
The planned date for review of the above guidance is August 2010.
This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full appraisal review.
The Institute has carried out a search for information relevant to this appraisal, and believes that it is appropriate for the guidance to be updated. However, we intend to review both appraisal guidance No 133; Omalizumab for severe persistent allergic asthma and the on-going technology appraisal of Omalizumab for the treatment of allergic asthma in children aged 6-12 together. This review will be scheduled into the work programme to take place after the publication of final guidance for the on-going technology appraisal of Omalizumab for the treatment of allergic asthma in children aged 6-12 (publication is anticipated to be October 2010).
Please see appendix A for a full list of the organisations we have contacted.
- Appendix A: provisional matrix of stakeholders
- Appendix B: proposal paper presented to the Institute's Guidance Executive
This page was last updated: 23 December 2010